Bristol Myers Squibb is a U.S.-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases. Its portfolio is concentrated in oncology, hematology, immunology, cardiovascular, and neuroscience, with a mix of marketed products and pipeline assets designed to support long-term growth.
71,1 %
14,6 %
−0,2 %
1.26
1.14
| % | |
|---|---|
| Oncology | 35% Immuno-oncology, combination regimens, and cell-therapy products for solid tumors and blood cancers. |
| Cardiovascular | 25% Anticoagulation and cardiac medicines, anchored by Eliquis and Camzyos. |
| Hematology | 20% Therapies for multiple myeloma, anemia, and other blood disorders, including legacy and growth products. |
| Immunology | 10% Autoimmune and inflammatory disease treatments sold to specialist prescribers and hospitals. |
| Other / Alliance Revenue | 10% Royalties, alliance-related revenues, and non-core product or licensing income. |
BMS sells primarily to wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies,...
Buy large volumes for downstream resale and inventory buffering; critical for U.S. and international channel access.
Dispense REMS-controlled and specialty medicines such as Revlimid, Pomalyst, and Camzyos.
Purchase and administer oncology, hematology, and infusion therapies used in specialist care settings.
Prescribe BMS medicines in oncology, cardiology, immunology, and hematology based on clinical evidence.
Influence formulary access, rebates, and reimbursement economics, especially in the U.S. and Europe.
BMS reports two main revenue regions: the United States and International markets, with the U.S...
BMS is focused on concentrating capital and R&D on transformational medicines in areas where it believes it has a...
Offsets patent and generic pressure by adding new assets and indications.
Eliquis, Opdivo, Reblozyl, Yervoy, and Orencia remain key revenue and cash drivers.
Improves margins and funds R&D and shareholder returns amid pricing pressure.
Creates a differentiated growth platform in precision oncology and diagnostics.
BMS faces heavy exposure to pricing pressure, reimbursement changes, and loss of exclusivity on a concentrated set of...
A majority of revenue and earnings comes from a small set of medicines, so any loss of exclusivity or demand decline can materially hurt results.
U.S. and international pricing restrictions, rebates, and channel changes can compress net selling prices and margins.
Generic entrants can rapidly erode sales volumes and pricing for mature products.
REMS programs and country-specific distribution rules can limit access and increase operational burden.
Business operations depend on digital systems and sensitive data, making outages or breaches potentially costly.
BMY · Pharmaceutical Preparations
Bristol Myers Squibb is a U.S.-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases.
BDX · Surgical & Medical Instruments & Apparatus
Becton, Dickinson and Company (BD) is a U.S.-based medical technology company with roots dating back to 1897 and incorporation in 1906.
HCMC · Tobacco Products
ROIV · Pharmaceutical Preparations
ONC · Pharmaceutical Preparations
MBRX · Pharmaceutical Preparations
: 11/08/2026